📊 SONM Key Takeaways
Is DNA X, Inc. (SONM) a Good Investment?
DNA X is in severe financial distress with negative stockholders equity (-$983K), indicating technical insolvency despite positive net income. The company is burning cash with negative operating cash flow (-$3.5M) and lacks adequate liquidity (current ratio 0.76x), suggesting inability to service debt or fund operations beyond the near term. The disconnect between positive net income ($6.3M) and negative operating cash flow indicates poor earnings quality, likely driven by non-operating gains rather than sustainable business performance.
DNA X, Inc. Key Strengths (SONM)
- Revenue growth of 14.5% year-over-year demonstrates top-line traction
- Maintains positive net income of $6.3M despite operational challenges
- Modest cash position of $1.2M provides limited runway
SONM Stock Risks: DNA X, Inc. Investment Risks
- Negative stockholders equity of -$983K indicates technical insolvency with liabilities exceeding assets
- Current ratio of 0.76x reflects critical liquidity crisis - unable to cover short-term obligations
- Negative operating cash flow of -$3.5M and free cash flow of -$3.7M show the company is burning cash unsustainably
- Operating margin of -8.2% reveals core business is unprofitable despite positive net income
- Large disconnect between GAAP net income and operating cash flow signals poor earnings quality and accounting anomalies
- Zero insider Form 4 filings in last 90 days indicates lack of insider confidence
- Interest coverage ratio of -27.6x shows inability to service debt from operations
Key Metrics to Watch
- Operating cash flow trajectory and path to profitability
- Stockholders equity recovery and refinancing capability
- Liquidity position and covenant compliance on $1.1M long-term debt
- Operating margin improvement and sustainability of revenue growth
DNA X, Inc. (SONM) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
SONM Profit Margin, ROE & Profitability Analysis
SONM vs Telecom Sector: How DNA X, Inc. Compares
How DNA X, Inc. compares to Telecom sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is DNA X, Inc. Stock Overvalued? SONM Valuation Analysis 2026
Based on fundamental analysis, DNA X, Inc. has mixed fundamental signals relative to the Telecom sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
DNA X, Inc. Balance Sheet: SONM Debt, Cash & Liquidity
SONM Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: DNA X, Inc.'s revenue has declined by 19% over the 5-year period, indicating business contraction. The most recent EPS of $-128.37 indicates the company is currently unprofitable.
SONM Revenue Growth, EPS Growth & YoY Performance
SONM Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $15.0M | -$2.5M | $-4.83 |
| Q2 2025 | $11.2M | -$6.6M | $-0.79 |
| Q1 2025 | $9.1M | $458.0K | $0.08 |
| Q3 2024 | $9.1M | $527.0K | $0.12 |
| Q2 2024 | $11.5M | $509.0K | $0.11 |
| Q1 2024 | $16.8M | $227.0K | $0.01 |
| Q3 2023 | $20.5M | $527.0K | $0.01 |
| Q2 2023 | $12.0M | $509.0K | $0.01 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
DNA X, Inc. Dividends, Buybacks & Capital Allocation
SONM SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for DNA X, Inc. (CIK: 0001178697)
📋 Recent SEC Filings
❓ Frequently Asked Questions about SONM
What is the AI rating for SONM?
DNA X, Inc. (SONM) has an AI grade of D with 95% confidence, based on fundamental analysis of SEC EDGAR filings.
What are SONM's key strengths?
Claude: Revenue growth of 14.5% year-over-year demonstrates top-line traction. Maintains positive net income of $6.3M despite operational challenges.
What are the risks of investing in SONM?
Claude: Negative stockholders equity of -$983K indicates technical insolvency with liabilities exceeding assets. Current ratio of 0.76x reflects critical liquidity crisis - unable to cover short-term obligations.
What is SONM's revenue and growth?
DNA X, Inc. reported revenue of $44.1M.
Does SONM pay dividends?
DNA X, Inc. does not currently pay dividends.
Where can I find SONM SEC filings?
Official SEC filings for DNA X, Inc. (CIK: 0001178697) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is SONM's EPS?
DNA X, Inc. has a diluted EPS of $5.01.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is SONM's fundamental grade?
Based on our AI fundamental analysis in May 2026, DNA X, Inc. has a D grade with 95% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is SONM stock overvalued or undervalued?
Valuation metrics for SONM: ROE of N/A (sector avg: 15%), net margin of 14.4% (sector avg: 14%). Compare these metrics with sector averages to assess valuation.
What is SONM's AI grade for 2026?
Our dual AI analysis gives DNA X, Inc. a combined D grade for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is SONM's free cash flow?
DNA X, Inc.'s operating cash flow is $-3.5M, with capital expenditures of $214.0K. FCF margin is -8.3%.
How does SONM compare to other Telecom stocks?
Vs Telecom sector averages: Net margin 14.4% (avg: 14%), ROE N/A (avg: 15%), current ratio 0.76 (avg: 1).